Jaguar Health, Inc.
JAGXHealthcare|Biotechnology|US
$0.40
-0.00 (-0.69%)
Cash / Share
$122.17
Financials
Financial Snapshot
Market Cap
$939.3K
Enterprise Value
$11.0M
Revenue (TTM)
$27.8M
Net Income (TTM)
-$36.6M
Cash & Investments
$6.6M
Net Cash
-$10.1M
Free Cash Flow (TTM)
-$6.8M
Operating CF (TTM)
-$6.7M
Debt/Equity
2.52
Cash Runway & Burn Rate
Cash on Hand
$6.6M
Quarterly Burn
$1.7M
Monthly Burn
$561.6K
Est. Runway
~3.9 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $951.0K | $520.7K | $2.6M | $3.5M | $8.1M | $17.1M | $5.5M | $6.5M | $8.0M | $968.0K | $6.6M | |
| Operating Cash Flow | -$14.4M | -$9.8M | -$22.7M | -$20.5M | -$15.3M | -$35.0M | -$33.1M | -$33.2M | -$29.4M | $5.8M | -$6.7M | |
| Free Cash Flow | -$14.5M | -$9.8M | -$22.7M | -$20.5M | -$15.3M | -$35.0M | -$34.8M | -$33.2M | -$29.6M | $5.8M | -$6.8M | |
| Capital Expenditure | -$104.2K | $0.00 | -$6.5K | $0.00 | -$7.0K | -$6.0K | -$1.7M | $0.00 | -$231.0K | -$25.0K | -$25.0K | |
| Financing Cash Flow | $5.3M | $10.7M | $24.5M | $21.8M | $19.5M | $43.9M | $23.2M | $34.2M | $31.2M | -$44.3M | $11.3M |
R&D Spending
R&D (TTM)
$25.2M
R&D Intensity
90.7%
R&D Growth vs Prior
+1.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $141.5K | $4.4M | $4.4M | $5.8M | $9.4M | $4.3M | $12.0M | $9.8M | $11.7M | $11.5M | $27.8M | |
| R&D Expense | $7.2M | $4.3M | $5.2M | $5.8M | $6.4M | $15.1M | $17.6M | $18.6M | $16.5M | $25.0M | $25.2M | |
| R&D % of Revenue | 5092.4% | 97.9% | 116.7% | 100.8% | 68.3% | 347.8% | 147.6% | 190.5% | 141.5% | 216.9% | 90.7% | |
| SG&A | $6.5M | $14.3M | $22.1M | $20.4M | $21.0M | $26.0M | $26.7M | $23.0M | $24.0M | $26.0M | $20.9M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $141.5K | $4.4M | $4.4M | $5.8M | $9.4M | $4.3M | $12.0M | $9.8M | $11.7M | $11.5M | $27.8M | |
| Cost of Revenue | $52.0K | $880.4K | $2.8M | $3.8M | $3.3M | $2.3M | $2.0M | $2.0M | $2.0M | $3.8M | $4.9M | |
| Gross Profit | $89.6K | $3.5M | $1.7M | $2.0M | $6.1M | $2.0M | $9.9M | $7.7M | $9.7M | $7.7M | $22.9M | |
| R&D | $7.2M | $4.3M | $5.2M | $5.8M | $6.4M | $15.1M | $17.6M | $18.6M | $16.5M | $25.0M | $25.2M | |
| SG&A | $6.5M | $14.3M | $22.1M | $20.4M | $21.0M | $26.0M | $26.7M | $23.0M | $24.0M | $26.0M | $20.9M | |
| Operating Income | -$13.6M | -$34.2M | -$30.8M | -$28.9M | -$26.6M | -$40.7M | -$34.4M | -$34.3M | -$30.8M | -$45.1M | -$25.1M | |
| Interest Expense | $985.5K | $1.2M | $2.6M | $5.7M | $2.8M | $8.4M | $12.7M | $6.4M | $231.0K | -$67.0K | $866.0K | |
| Pretax Income | -$14.7M | -$35.1M | -$32.1M | -$38.5M | -$33.8M | -$52.6M | -$48.4M | -$41.9M | -$39.3M | -$54.0M | -$36.9M | |
| Net Income | -$14.7M | -$22.0M | -$32.1M | -$38.5M | -$33.8M | -$52.6M | -$47.5M | -$41.3M | -$38.5M | -$53.4M | -$36.6M | |
| EPS (Diluted) | -251163000000.00 | -94883900000.00 | -27162800000.00 | -1596460000.00 | -177212295.00 | -69476385.00 | -28492920.00 | -1409880.00 | -68611.05 | -12059.25 | -5482.20 | |
| EBITDA | -$13.7M | -$11.1M | -$28.2M | -$30.9M | -$28.7M | -$42.4M | -$33.4M | -$31.5M | -$36.7M | -$51.7M | -$40.0M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $951.0K | $520.7K | $2.6M | $3.5M | $8.1M | $17.1M | $5.5M | $6.5M | $8.0M | $968.0K | $6.6M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $2.6M | $3.8M | $8.1M | $9.5M | $17.8M | $28.4M | $22.3M | $28.0M | $32.2M | $20.3M | $17.5M | |
| Total Assets | $3.6M | $43.6M | $41.0M | $36.4M | $42.8M | $53.3M | $47.5M | $50.8M | $53.4M | $38.3M | $34.2M | |
| Total Current Liabilities | $4.2M | $15.4M | $26.7M | $15.4M | $13.2M | $15.5M | $30.3M | $14.0M | $19.7M | $40.7M | $25.4M | |
| Long-Term Debt | $1.8M | $11.0M | $0.00 | $450.0K | $12.4M | $25.0M | $17.7M | $31.0M | $23.5M | $15.1M | $1.7M | |
| Total Liabilities | $6.0M | $26.4M | $35.7M | $25.7M | $25.6M | $41.4M | $48.8M | $45.9M | $46.9M | $57.0M | $29.3M | |
| Stockholders' Equity | -$2.5M | $17.3M | $5.4M | $10.7M | $17.2M | $11.6M | -$657.0K | $5.0M | $7.3M | -$17.3M | $6.6M | |
| Retained Earnings | -$40.4M | -$62.4M | -$94.6M | -$133.1M | -$166.9M | -$219.5M | -$266.9M | -$308.2M | -$346.5M | -$399.9M | -$403.7M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$14.4M | -$9.8M | -$22.7M | -$20.5M | -$15.3M | -$35.0M | -$33.1M | -$33.2M | -$29.4M | $5.8M | -$6.7M | |
| Capital Expenditure | -$104.2K | $0.00 | -$6.5K | $0.00 | -$7.0K | -$6.0K | -$1.7M | $0.00 | -$231.0K | -$25.0K | -$25.0K | |
| Free Cash Flow | -$14.5M | -$9.8M | -$22.7M | -$20.5M | -$15.3M | -$35.0M | -$34.8M | -$33.2M | -$29.6M | $5.8M | -$6.8M | |
| Investing Cash Flow | $2.4M | -$1.3M | -$6.5K | $0.00 | -$7.0K | -$6.0K | -$1.7M | $0.00 | -$231.0K | $149.0K | -$41.0K | |
| Financing Cash Flow | $5.3M | $10.7M | $24.5M | $21.8M | $19.5M | $43.9M | $23.2M | $34.2M | $31.2M | -$44.3M | $11.3M | |
| Issuance of Stock | $8.8M | $10.3M | $16.7M | $6.6M | $1.9M | $33.6M | $20.5M | $32.1M | $31.9M | $1.9M | $589.0K | |
| Repurchase of Stock | $0.00 | $0.00 | -$30.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$31.1M | -$31.1M | |
| Net Debt Issuance | -$2.5M | $377.9K | $783.5K | -$100.0K | $5.7M | $9.1M | $3.9M | -$100.0K | -$100.0K | -$20.9M | -$30.7M | |
| Stock Based Comp. | $717.9K | $814.6K | $2.0M | $3.0M | $2.8M | $4.0M | $3.3M | $2.1M | $1.6M | -$810.0K | -$1.1M | |
| Net Change in Cash | -$6.7M | -$430.3K | $1.8M | $1.3M | $4.2M | $9.0M | -$11.6M | $1.0M | $1.5M | -$38.4M | $4.4M |
Dilution Tracker
Shares outstanding grew 2037138.6% over 5 years — significant dilution
Shares Outstanding
2M
5-Year Share Growth
+2037138.6%
Stock Issuance (TTM)
$589.0K
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | |
| Change vs Prior % | — | 296.6% | 407.0% | 2267.5% | 678.2% | 247.1% | 120.0% | 1641.3% | 1834.5% | 692.0% | 1114.1% | |
| Stock Issuance | $8.8M | $10.3M | $16.7M | $6.6M | $1.9M | $33.6M | $20.5M | $32.1M | $31.9M | $1.9M | $589.0K | |
| Stock Repurchase | $0.00 | $0.00 | -$30.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$31.1M | -$31.1M | |
| Stock Based Comp. | $717.9K | $814.6K | $2.0M | $3.0M | $2.8M | $4.0M | $3.3M | $2.1M | $1.6M | -$810.0K | -$1.1M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 63.3% | 79.8% | 37.4% | 33.9% | 65.1% | 46.2% | 83.1% | 79.1% | 83.3% | 67.2% | 82.3% | |
| Operating Margin % | -9599.8% | -785.3% | -698.0% | -501.3% | -283.9% | -939.1% | -287.8% | -351.3% | -263.8% | -391.9% | -90.2% | |
| Net Margin % | -10410.9% | -503.7% | -727.9% | -667.3% | -360.2% | -1213.3% | -396.9% | -423.1% | -329.3% | -464.2% | -131.8% | |
| EBITDA Margin % | -9680.9% | -255.2% | -638.5% | -534.5% | -306.2% | -977.3% | -279.2% | -323.0% | -313.6% | -449.4% | -143.7% | |
| FCF Margin % | -10258.4% | -225.3% | -514.9% | -354.2% | -162.9% | -806.8% | -290.9% | -340.6% | -253.4% | 50.2% | -24.3% | |
| ROE % | 600.4% | -127.3% | -597.2% | -361.1% | -196.5% | -453.0% | 7222.8% | -832.5% | -528.4% | 309.1% | 762.5% | |
| ROA % | -413.5% | -50.4% | -78.3% | -105.8% | -78.9% | -98.7% | -100.0% | -81.4% | -72.0% | -139.4% | -107.2% | |
| ROIC % | -943.5% | -63.6% | -101.2% | -102.9% | -79.8% | -98.8% | -102.8% | -81.7% | -66.9% | -178.3% | -109.7% | |
| R&D / Revenue % | 5092.4% | 97.9% | 116.7% | 100.8% | 68.3% | 347.8% | 147.6% | 190.5% | 141.5% | 216.9% | 90.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -45.2% | 2981.6% | 1.3% | 30.8% | 62.5% | -53.8% | 175.8% | -18.4% | 19.8% | -1.5% | |
| Gross Profit | -33.6% | 3786.7% | -52.6% | 18.7% | 211.6% | -67.2% | 396.4% | -22.3% | 26.0% | -20.5% | |
| Operating Income | -9.2% | -152.1% | 10.0% | 6.1% | 7.9% | -52.8% | 15.5% | 0.4% | 10.1% | -46.3% | |
| Net Income | 9.6% | -49.1% | -46.3% | -19.9% | 12.3% | -55.6% | 9.8% | 13.0% | 6.8% | -38.8% | |
| EPS (Diluted) | 50.0% | 62.2% | 71.4% | 94.1% | 88.9% | 60.8% | 59.0% | 95.1% | 95.1% | 82.4% | |
| Operating Cash Flow | -0.7% | 31.8% | -131.4% | 10.0% | 25.3% | -128.9% | 5.3% | -0.4% | 11.6% | 119.7% | |
| Free Cash Flow | -1.2% | 32.3% | -131.4% | 10.0% | 25.3% | -128.8% | 0.6% | 4.4% | 10.9% | 119.5% | |
| R&D Expense | 11.3% | -40.8% | 20.7% | 12.9% | 10.2% | 135.1% | 17.0% | 5.4% | -11.0% | 50.9% | |
| SG&A Expense | 6.0% | 121.6% | 54.3% | -7.6% | 2.7% | 23.8% | 2.7% | -13.7% | 4.2% | 8.3% | |
| Total Assets | -71.3% | 1124.5% | -5.9% | -11.3% | 17.7% | 24.3% | -10.9% | 7.0% | 5.2% | -28.3% | |
| Book Value / Share | -131.3% | 277.3% | -93.8% | -91.6% | -79.3% | -80.1% | -105.2% | 120.7% | -93.1% | -136.3% | |
| Debt | -34.7% | 322.0% | -2.0% | -53.0% | 114.3% | 81.2% | 18.6% | 6.5% | -1.5% | 19.4% | |
| Diluted Shares | 78.0% | 296.6% | 407.0% | 2267.5% | 678.2% | 247.1% | 120.0% | 1641.3% | 1834.5% | 692.0% |
Valuation
P/E (TTM)At Loss
P/S0.03
10Y Low / Med / High0.12 / 0.46 / 18.46
P/B0.00
10Y Low / Med / High0.12 / 0.23 / 1.33
EV/EBITDAAt Loss
EV/Revenue0.40
10Y Low / Med / High0.93 / 3.31 / 39.21
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$122.17
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.18 | -0.09 | -0.03 | -0.03 | -0.27 | -0.29 | -0.06 | -0.03 | -0.19 | -0.04 | -0.00 | |
| P/S Ratio | 18.46 | 0.46 | 0.25 | 0.23 | 1.12 | 3.58 | 0.24 | 0.12 | 0.64 | 0.19 | 0.03 | |
| P/B Ratio | -1.06 | 0.12 | 0.21 | 0.12 | 0.61 | 1.33 | -4.34 | 0.23 | 1.02 | -0.13 | 0.00 | |
| EV/EBITDA | -0.41 | -1.61 | -0.52 | -0.17 | -0.65 | -0.66 | -0.97 | -1.01 | -0.98 | -0.87 | -0.28 | |
| EV/Revenue | 39.21 | 4.11 | 3.31 | 0.93 | 1.98 | 6.42 | 2.69 | 3.26 | 3.08 | 3.89 | 0.40 |
Analyst Estimates & Quality
Altman Z-Score
-20.04
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 |
|---|---|---|
| Revenue | $2.5M | $4.1M |
| Net Income | -$202.5K | -$455.6K |
| EPS | $-45.57 | $-102.53 |
| # Analysts (EPS) | 1 | 1 |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Mytesi | $9.3M | $3.3M | $11.7M | $9.6M | $11.3M | $11.0M |
| Neonorm | $76.0K | $62.0K | $48.0K | $42.0K | $28.0K | $35.0K |
| License | — | — | — | — | $129.0K | $172.0K |